Join Dr. Brittney Mills as she explains what criteria AbbVie’s preformulation department screens for in their antibody candidates. Learn how her group uses high-throughput screening tools like the Prometheus to select molecules and conditions with the best developability profiles from large screens, while using less material and requiring less time to get their results.
You’ll learn about:
- Why it’s important to screen for Drug-Like Properties (DLPs) of candidates
- Which criteria Abbvie uses to assess DLPs of their candidates, and what high-throughput tools they use to do it
- How thermal and colloidal stability assessment during preformulation correlates with accelerated stability studies for long-term stability prediction
- The benefits of Prometheus to screen for antibody DLPs at early stages of development and how they stack up against alternative methods such as DSC
Why is it important for Biologics development:
Assessing the so-called Drug-Like properties (DLPs) of antibody candidates early in their development ensures they are fit to move forward in the pipeline. Thermal and colloidal stability of the candidates are two DLPs used to select those that exhibit the best developability qualities.
Make improved developability decisions about your antibodies and formulations with high-throughput, high-precision tools that allow for low sample consumption and faster time to results.
Want to know about high precision tools for the combined characterization of thermal and colloidal stability of biologics? Learn more about Prometheus Panta
